Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0524A in Primary Hypercholesterolemia or Mixed Hyperlipidemia
NCT00269204Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2005
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of laropiprant in hypercholesterolemia and mixed hyperlipidemia (3 arms), sponsored by Merck & Co. Primary endpoints: Reductions of LDL-C concentrations at 24 weeks and Better tolerability at 24 weeks. Started Dec 2005; status: completed.
02
Drugs
laropiprant
03
Conditions
hypercholesterolemiamixed hyperlipidemia
Beyond the preview
Go deeper on NCT00269204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00269204.